



1-800-533-1710

Bcell/Antibody Deficiency GenePanel

BCELL

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER N022000306
PATIENT ID X100420056	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY ATLAS TEST
COLLECTED 5/22/2023, 6:33 AM	RECEIVED 5/22/2023, 12:21 PM	REPORTED 5/24/2023, 10:26 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER X100420056 CLIENT MRN 321

TEST DESCRIPTION

Evaluation of 61 genes associated with inherited B-cell disorders and humoral immunodeficiency

SPECIMEN

WB Whole Blood

RESULT SUMMARY

Pathogenic Variant Detected

RESULT

Gene (Transcript)	Variant	Zygosity	Classification
BTK (NM_000061.2)	c.1079_1082del p.Asn360Thrfs*42 (p.N360Tfs*42) ChrX(GRCh37):g.100613318_100613321del	Hemizygous	Pathogenic

The following hemizygous PATHOGENIC variant was detected:

BTK (NM_000061.2), chrX(GRCh37):g.100613318_100613321del, c.1079_1082del, p.Asn360Thrfs*42 (p.N360Tfs*42)

No additional reportable variants were detected within all other tested genes. See the Genes Analyzed section for a complete list of genes evaluated by this assay.

INTERPRETATION

BTK c.1079_1082del (p.Asn360Thrfs*42), PATHOGENIC

The hemizygous c.1079_1082del (p.Asn360Thrfs*42) small deletion in the BTK gene (MIM:300300) is classified as pathogenic. The BTK gene encodes Bruton tyrosine kinase (BTK), a protein essential for the development and maturation of B cells. Pathogenic variants in this gene are associated with X-linked agammaglobulinemia (XLA). This variant is predicted to cause premature protein truncation due to a frameshift and is expected to result in loss-of-function. To our knowledge, this variant has not been reported in affected individuals. However, other truncating variants in the BTK gene have been associated with disease. This variant is absent from large control databases (1,2). This result is supportive of a diagnosis of X-linked agammaglobulinemia (XLA) for this individual. Clinical correlation is recommended.

This result should be interpreted in the context of clinical findings, family history, and other laboratory testing.

Consultation with a genetics professional is recommended for interpretation of this result and to determine whether reproductive risk assessment and familial testing may be of benefit to this family. Genetic testing for family members is available by ordering FMTT / Familial Mutation, Targeted Testing for the specific variant(s) detected. Please contact the laboratory at 1-800-533-1710 or the online test catalog at www.mayocliniclabs.com for information about FMTT.

PATIENT NAME	TESTRNV, IMPLEMENTATION	23-25058
--------------	-------------------------	----------



1-800-533-1710

Bcell/Antibody Deficiency GenePanel

BCELL

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER N022000306
PATIENT ID X100420056	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY ATLAS TEST
COLLECTED 5/22/2023, 6:33 AM	RECEIVED 5/22/2023, 12:21 PM	REPORTED 5/24/2023, 10:26 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER X100420056 CLIENT MRN 321

REFERENCES:

- 1) dbSNP: www.ncbi.nlm.nih.gov/snp; Sherry ST, Ward M and Sirotkin K. dbSNP-Database for Single Nucleotide Polymorphisms and Other Classes of Minor Genetic Variation. Genome Res. 1999;9:677-679 (PMID 10447503)
- 2) gnomAD Browser: gnomad.broadinstitute.org/; Karczewski K, Francioli LC, MacArthur DG, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443 (PMID 32461654)

METHOD

Next generation sequencing (NGS) and/or Sanger sequencing was performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known pathogenic variants. NGS and/or a polymerase chain reaction (PCR)-based quantitative method was performed to test for the presence of deletions and duplications in the genes analyzed. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for indels less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. See the Genes Analyzed field for a list of genes tested.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria. See www.mayocliniclabs.com (TEST ID BCELL) for details regarding genes with regions not routinely covered.

GENES ANALYZED

ADA, ADA2, AICDA, ATP6AP1, BLNK, BTK, CARD11, CD19, CD27, CD40, CD40LG, CD70, CD79A, CD79B, CD81, CDCA7, CTLA4, CR2, CXCR4, DCLRE1C, DNMT3B, GATA2, ICOS, IGHM, IGLL1, IKBKG, IKZF1, IKZF3, IL21, IL21R, IRF2BP2, KDM6A, KMT2A, KMT2D, LIG1, LRBA, MOGS, MS4A1, NFKB1, NFKB2, PIK3CD, PIK3R1, PLCG2, PRKCD, RAC2, RAG1, RAG2, RNF168, SEC61A1, SH2D1A, SH3KBP1, SLC39A7, TCF3, TNFRSF13B, TNFRSF13C, TNFSF12, TNFSF13, TOP2B, TRNT1, UNG and XIAP

DISCLAIMER

Clinical Correlations

An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de-identified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

PATIENT NAME	TESTRNV, IMPLEMENTATION	23-25058
--------------	-------------------------	----------



1-800-533-1710

Bcell/Antibody Deficiency GenePanel

BCELL

PATIENT NAME TESTRNV, IMPLEMENTATION					ORDER NUMBER N022000306
PATIENT ID X100420056	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY ATLAS TEST	
COLLECTED 5/22/2023, 6:33 AM	RECEIVED 5/22/2023, 12:21 PM	REPORTED 5/24/2023, 10:26 AM			
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100420056	
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321	

If testing was performed because of a clinically significant family history it is often useful to first test an affected family member. Detection of a reportable variant(s) in an affected family member would allow for more informative testing of at risk individuals.

To discuss the availability of further testing options or for assistance in the interpretation of these results, Mayo Clinic Laboratory genetic counselors can be contacted at 1-800-533-1710.

Technical Limitations

Next generation sequencing may not detect all types of genomic variants. In rare cases, false negative or false positive results may occur. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria.

Additionally, low level mosaic variants may not be detected.

This test is not designed to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. Please refer to the Targeted Genes and Methodology Details for the B-cell/Antibody Deficiency Panel in the Special Instructions section of the Test Catalog for the most up to date list of genes included in this test.

Reclassification of Variants Policy

See www.mayocliniclabs.com (TEST ID BCELL) for information regarding the laboratory's policy for reclassification of variants.

Variant Evaluation

Variant curation is performed using published ACMG-AMP recommendations as a guideline. Other gene-specific guidelines may also be considered. Variants classified as benign or likely benign are not reported.

Results from in silico evaluation tools may change over time and should be interpreted with caution and professional clinical judgment.

TEST CLASSIFICATION

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

PATIENT NAME	TESTRNV, IMPLEMENTATION	23-25058
--------------	-------------------------	----------



1-800-533-1710

Bcell/Antibody Deficiency GenePanel

BCELL

PATIENT NAME TESTRNV, IMPLEMENTATION					ORDER NUMBER N022000306
PATIENT ID X100420056	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY ATLAS TEST	
COLLECTED 5/22/2023, 6:33 AM	RECEIVED 5/22/2023, 12:21 PM	REPORTED 5/24/2023, 10:26 AM			
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100420056	
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321	

RELEASED BY

Ann Marie Moyer, M.D., Ph.D.

Code : MCR Laboratory : Mayo Clinic Laboratories - Rochester Main Campus Address : 200 FIRST STREET SW

Lab Director : WILLIAM G MORICE MD, PHD CLIA Certificate : 24D0404292 ROCHESTER MN 55905